MARKET

IDRA

IDRA

Idera Pharma
NASDAQ
0.3936
+0.0187
+4.99%
Closed 16:00 10/04 EDT
OPEN
0.3700
PREV CLOSE
0.3749
HIGH
0.4000
LOW
0.3700
VOLUME
142.51K
TURNOVER
31.37K
52 WEEK HIGH
1.060
52 WEEK LOW
0.2950
MARKET CAP
20.88M
P/E (TTM)
-1.0041
1D
5D
1M
3M
1Y
5Y
Why Sunlight Financial Shares Are Trading Lower By 59%, Here Are 54 Stocks Moving In Thursday's Mid-Day Session
Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares jumped 52% to $2.1325 after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target.
Benzinga · 5d ago
Idera Pharma Acquires Rare Disease Player, Names New CEO
Idera Pharmaceuticals Inc (NASDAQ: IDRA) acquired Aceragen Inc, a privately-held biotechnology company focused on rare, orphan pulmonary, and rheumatic diseases.
Benzinga · 5d ago
Why Twin Vee Powercats Is Trading Lower By Over 30%; Here Are 30 Stocks Moving Premarket
Gainers Windtree Therapeutics, Inc (NASDAQ: WINT) rose 50.7% to $0.4827 in pre-market trading after the company said Istaroxime Phase 2 study in early cardiogenic shock was published in the European Journal of Heart Failure.
Benzinga · 5d ago
BRIEF-Idera Pharmaceuticals Acquires Aceragen
BRIEF-Idera Pharmaceuticals Acquires Aceragen
Reuters · 5d ago
Durham CEO now leads public company following acquisition
A Durham-based drug developer has been bought by a public company a little more than a year after launching.
American City Business Journals · 6d ago
Idera Pharmaceuticals completes acquisition of Aceragen
Idera Pharmaceuticals (NASDAQ:IDRA) has completed the...
Seekingalpha · 6d ago
Idera Pharmaceuticals Acquires Aceragen; Terms Not Disclosed
Idera Pharmaceuticals, Inc. ("Idera," the "Company," "we," "us," or "our") (NASDAQ:IDRA) today announced it has completed the acquisition of Aceragen, Inc.
Benzinga · 6d ago
Idera Pharmaceuticals Acquires Aceragen
Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024 Conference call and webcast today at 5:00 p.m. ET EXTON, Pa. and DURHAM, N.C., Sept. 28, 2022 (GLOBE...
GlobeNewswire · 6d ago
More
About IDRA
Idera Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the clinical development, and commercialization of drug candidates for rare diseases and oncology. The Company is developing tilsotolimod, an investigational Toll-like receptor 9 agonist, for the treatment of advanced solid tumors. Its lead investigational product, tilsotolimod, demonstrated activity in various pre-clinical models and is in clinical development across several oncology indications. These indications include anti-PD-1 refractory advanced melanoma, microsatellite-stable colorectal cancer (MSS-CRC, phase II), and recurrent/metastatic head & neck squamous cell carcinoma (HNSCC, phase I/II). Tilsotolimod is used for the treatment of anti-PD-1 refractory melanoma, in combination with ipilimumab, as well as for the treatment of stage IIb-IV melanoma. Its clinical trials include ILLUMINATE-204, ILLUMINATE-206 and ILLUMINATE-101. It is also focused on rare, orphan pulmonary and rheumatic diseases.

Webull offers kinds of Idera Pharmaceuticals Inc stock information, including NASDAQ:IDRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IDRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IDRA stock methods without spending real money on the virtual paper trading platform.